Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 16.42 Billion KRW | 382.68% |
| 2022 | 3.4 Billion KRW | 112.22% |
| 2021 | -27.83 Billion KRW | -503.35% |
| 2020 | -4.61 Billion KRW | 37.15% |
| 2019 | -7.34 Billion KRW | -273.67% |
| 2018 | 4.22 Billion KRW | -72.14% |
| 2017 | 15.16 Billion KRW | 437.3% |
| 2016 | 2.82 Billion KRW | -43.47% |
| 2015 | 4.99 Billion KRW | 178.65% |
| 2014 | -6.35 Billion KRW | -142.01% |
| 2013 | -2.62 Billion KRW | -140.92% |
| 2012 | 6.41 Billion KRW | -31.47% |
| 2011 | 9.35 Billion KRW | -24.25% |
| 2010 | 12.35 Billion KRW | -20.24% |
| 2009 | 15.48 Billion KRW | 3.81% |
| 2008 | 14.92 Billion KRW | -4.84% |
| 2007 | 15.67 Billion KRW | 3.09% |
| 2006 | 15.2 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -14.21 Billion KRW | -186.56% |
| 2024 Q2 | -5.44 Billion KRW | 61.71% |
| 2023 Q4 | 16.42 Billion KRW | -26.09% |
| 2023 Q2 | 27.1 Billion KRW | 42.36% |
| 2023 FY | 16.42 Billion KRW | 382.68% |
| 2023 Q1 | 19.03 Billion KRW | 459.41% |
| 2023 Q3 | 22.22 Billion KRW | -17.99% |
| 2022 Q3 | 2.87 Billion KRW | 821.73% |
| 2022 Q1 | -14.54 Billion KRW | 47.75% |
| 2022 FY | 3.4 Billion KRW | 112.22% |
| 2022 Q2 | -398.33 Million KRW | 97.26% |
| 2022 Q4 | 3.4 Billion KRW | 18.36% |
| 2021 Q4 | -27.83 Billion KRW | -59.21% |
| 2021 FY | -27.83 Billion KRW | -503.35% |
| 2021 Q1 | -9.98 Billion KRW | -116.37% |
| 2021 Q2 | -7.8 Billion KRW | 21.86% |
| 2021 Q3 | -17.48 Billion KRW | -124.15% |
| 2020 FY | -4.61 Billion KRW | 37.15% |
| 2020 Q1 | -3.78 Billion KRW | 48.5% |
| 2020 Q3 | 3.13 Billion KRW | -52.7% |
| 2020 Q4 | -4.61 Billion KRW | -247.12% |
| 2020 Q2 | 6.63 Billion KRW | 275.39% |
| 2019 Q4 | -7.34 Billion KRW | -230.08% |
| 2019 FY | -7.34 Billion KRW | -273.67% |
| 2019 Q1 | -7.16 Billion KRW | -269.52% |
| 2019 Q2 | 5.19 Billion KRW | 172.51% |
| 2019 Q3 | 5.64 Billion KRW | 8.6% |
| 2018 Q3 | 12.22 Billion KRW | -23.12% |
| 2018 Q1 | 11.48 Billion KRW | -24.31% |
| 2018 Q2 | 15.9 Billion KRW | 38.51% |
| 2018 FY | 4.22 Billion KRW | -72.14% |
| 2018 Q4 | 4.22 Billion KRW | -65.43% |
| 2017 Q1 | 2.61 Billion KRW | -7.3% |
| 2017 Q4 | 15.16 Billion KRW | 189.31% |
| 2017 Q3 | 5.24 Billion KRW | 93.08% |
| 2017 Q2 | 2.71 Billion KRW | 3.77% |
| 2017 FY | 15.16 Billion KRW | 437.3% |
| 2016 Q1 | 510.83 Million KRW | 0.0% |
| 2016 Q4 | 2.82 Billion KRW | 170.78% |
| 2016 Q3 | -3.98 Billion KRW | -261.86% |
| 2016 Q2 | 2.46 Billion KRW | 382.42% |
| 2016 FY | 2.82 Billion KRW | -43.47% |
| 2015 Q2 | 3.35 Billion KRW | 79.62% |
| 2015 Q1 | 1.86 Billion KRW | 129.44% |
| 2015 Q3 | 3.43 Billion KRW | 2.3% |
| 2015 FY | 4.99 Billion KRW | 178.65% |
| 2014 Q1 | -893.24 Million KRW | 65.96% |
| 2014 Q2 | -567.18 Million KRW | 36.5% |
| 2014 FY | -6.35 Billion KRW | -142.01% |
| 2014 Q4 | -6.35 Billion KRW | -58.83% |
| 2014 Q3 | -3.99 Billion KRW | -604.92% |
| 2013 FY | -2.62 Billion KRW | -140.92% |
| 2013 Q2 | 5.59 Billion KRW | -3.55% |
| 2013 Q1 | 5.8 Billion KRW | -9.53% |
| 2013 Q4 | -2.62 Billion KRW | -707.56% |
| 2013 Q3 | 431.87 Million KRW | -92.28% |
| 2012 Q4 | 6.41 Billion KRW | 0.0% |
| 2012 FY | 6.41 Billion KRW | -31.47% |
| 2012 Q1 | 8.79 Billion KRW | 0.0% |
| 2011 Q1 | 19.64 Billion KRW | 59.02% |
| 2011 Q2 | 19.41 Billion KRW | -1.17% |
| 2011 Q3 | 12.71 Billion KRW | -34.54% |
| 2011 FY | 9.35 Billion KRW | -24.25% |
| 2010 Q4 | 12.35 Billion KRW | -2.8% |
| 2010 Q1 | 14.79 Billion KRW | -4.45% |
| 2010 FY | 12.35 Billion KRW | -20.24% |
| 2010 Q2 | 13.66 Billion KRW | -7.65% |
| 2010 Q3 | 12.71 Billion KRW | -7.01% |
| 2009 Q3 | 18.88 Billion KRW | 3.97% |
| 2009 Q4 | 15.48 Billion KRW | -17.98% |
| 2009 Q2 | 18.16 Billion KRW | 25.54% |
| 2009 Q1 | 14.46 Billion KRW | -3.04% |
| 2009 FY | 15.48 Billion KRW | 3.81% |
| 2008 Q2 | 16.6 Billion KRW | 1.82% |
| 2008 Q3 | 15.41 Billion KRW | -7.12% |
| 2008 Q1 | 16.3 Billion KRW | 0.0% |
| 2008 FY | 14.92 Billion KRW | -4.84% |
| 2008 Q4 | 14.92 Billion KRW | -3.23% |
| 2007 Q2 | 16.1 Billion KRW | 0.0% |
| 2007 Q3 | 16.79 Billion KRW | 4.23% |
| 2007 FY | 15.67 Billion KRW | 3.09% |
| 2006 FY | 15.2 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -86.601% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 97.129% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 94.716% |
| HANDOK Inc. | 283.45 Billion KRW | 94.205% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 18.17% |
| Yuhan Corporation | -69.18 Billion KRW | 123.74% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 91.531% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 545.63% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 96.828% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 150.645% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 78.295% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 55.412% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 80.096% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 34.583% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -86.601% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 110.276% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 91.826% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 90.392% |
| JW Holdings Corporation | 480.68 Billion KRW | 96.583% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 90.02% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -13875.074% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 89.36% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -598.549% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 28.591% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 90.613% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 68.398% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -86.601% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 89.624% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 95.414% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 89.36% |
| Yuhan Corporation | -69.18 Billion KRW | 123.74% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 87.922% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 72.475% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 96.173% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 89.36% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 85.869% |
| CKD Bio Corp. | 143.29 Billion KRW | 88.538% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 85.849% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 168.262% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 136.717% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -598.549% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 96.116% |
| Boryung Corporation | 187.72 Billion KRW | 91.251% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 122.863% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 78.295% |
| JW Lifescience Corporation | 26.09 Billion KRW | 37.046% |